Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2022-10-26 AGM Information
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting 16 pages 604.0KB
AGM Information Classification · 100% confidence The document is titled '2022 Annual General Meeting' and includes detailed information about the AGM such as the date, location, agenda, voting procedures, resolutions to be considered, and proxy information. It contains the Notice of Annual General Meeting and an Explanatory Statement, which are materials typically distributed to shareholders prior to or in conjunction with the AGM. The document references the Annual Report for the financial year ended 30 June 2022 but does not contain the report itself; rather, it states that the report is available on the company's website or by contacting the company. The document also includes resolutions for shareholder voting, including adoption of the Remuneration Report and election of a director, which are standard AGM agenda items. The length of the document (15,000 characters) and its content indicate it is not a brief announcement but the actual AGM meeting materials. Therefore, this document fits the category of AGM Information (AGM-R) as it is the notice and explanatory materials for the Annual General Meeting, not the Annual Report itself or a voting results announcement.
2022-10-26 English
Investor Presentation 13 pages 988.1KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's products, pipeline, financial position, market opportunities, and development plans. It includes forward-looking statements, financial metrics like cash position and market capitalization, and strategic updates. There is no indication that this is a regulatory filing, earnings release, or annual report. The length is substantial (15,000 characters), and the content is consistent with a presentation aimed at investors to inform them about the company's business and prospects. Therefore, the document fits the definition of an Investor Presentation (IP).
2022-10-26 English
Canadian Patent Granted for BARD1 Technology 1 page
Regulatory Filings Classification · 95% confidence The document is a short announcement (3261 characters) about the granting of a Canadian patent for a technology related to lung cancer diagnosis by INOVIQ Limited. It contains no financial data, no regulatory filings, no management or board changes, no voting results, no earnings or financial reports, and no detailed presentations. It is a straightforward corporate announcement about intellectual property rights. The document does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial or governance filings. It is not a report publication announcement since it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2022-10-26 English
Receipt of R&D Tax Incentive Refund 1 page 140.6KB
Regulatory Filings Classification · 95% confidence The document is a short announcement about the receipt of an R&D tax incentive refund by INOVIQ Limited for the 2021 financial year. It does not contain any financial statements, detailed financial performance data, or substantive analysis. It is a regulatory update about a government refund received, not a report or detailed financial disclosure. The document length is only 1723 characters, indicating it is a brief announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-10-13 English
INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform 4 pages 304.3KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from INOVIQ Limited about a contract research agreement with Nicoya Lifesciences to develop a SubB2M-based test on Nicoya's Alto digital SPR platform. It discusses the technology, the research agreement, previous test results, market context, and forward-looking statements. There are no financial statements, earnings data, or regulatory filings typical of annual or interim reports. It is not a transcript of a call, nor a voting result or director dealing. The document is a corporate announcement about a research and development collaboration and technology update. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2022-10-12 English
Appendix 4G and Corporate Governance Statement 19 pages 467.3KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 30 June 2022. The document explicitly states it is not a substitute for the corporate governance statement but serves as a verification tool and key to disclosures. It does not contain the full corporate governance statement or the annual report itself but rather a structured checklist and references to where disclosures can be found (e.g., website URLs or annual report pages). The document is 15,000 characters long, which is substantial but still functions as an appendix or supplementary governance disclosure rather than a full report. Given these characteristics, this document fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. It is not an Annual Report (10-K) or a Regulatory Filing (RNS) because it is a formal governance disclosure document required by ASX rules, specifically Appendix 4G, which is a recognized governance reporting format in Australia.
2022-10-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.